{"organizations": [], "uuid": "487828a3c8787900118792a16b1897e092088e14", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sierra-oncology-significantly-expa/brief-sierra-oncology-significantly-expands-clinical-development-program-idUSFWN1QH0OO", "country": "US", "domain_rank": 408, "title": "BRIEF-Sierra Oncology Significantly Expands Clinical Development Program", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T14:26:00.000+02:00", "replies_count": 0, "uuid": "487828a3c8787900118792a16b1897e092088e14"}, "author": "", "url": "https://www.reuters.com/article/brief-sierra-oncology-significantly-expa/brief-sierra-oncology-significantly-expands-clinical-development-program-idUSFWN1QH0OO", "ord_in_thread": 0, "title": "BRIEF-Sierra Oncology Significantly Expands Clinical Development Program", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "sierra oncology inc", "sentiment": "none"}, {"name": "program reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "sierra oncology", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 27, 2018 / 12:29 PM / in 13 minutes BRIEF-Sierra Oncology Significantly Expands Clinical Development Program Reuters Staff * SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM * SIERRA ONCOLOGY INC - ADDING NEW SRA737 MONOTHERAPY COHORT FOR CCNE1-DRIVEN OVARIAN CANCER * SIERRA ONCOLOGY INC - SRA141 IND SUBMISSION PLANNED IN H2 2018 * SIERRA ONCOLOGY - ONGOING SRA737 CLINICAL STUDIES EXPANDED TO TARGET AGGREGATE ENROLLMENT OF 200 PATIENTS ACROSS TEN CANCER INDICATIONS * SIERRA ONCOLOGY - TO INITIATE PHASE 1B/2 TRIAL IN Q4 TO EVALUATE SRA737 WITH ZEJULA TO TREAT METASTATIC CASTRATION-RESISTANT PROSTATE CANCER * SIERRA ONCOLOGY - EXPANDING NUMBER OF ACTIVE SITES RECRUITING PATIENTS INTO SRA737-01 PHASE 1/2 MONOTHERAPY TRIAL FROM 3 TO 15 * SIERRA ONCOLOGY - MAJORITY OF REPORTED ADVERSE EVENTS IN SRA737-02 PHASE 1/2 LDG COMBINATION TRIAL HAVE BEEN GRADE 1 OR GRADE 2 IN SEVERITY * SIERRA ONCOLOGY - ONLY ONE GRADE 3 TREATMENT RELATED AE (NEUTROPENIA) WAS OBSERVED, AT 40 MG SRA737/300 MG/M(2) GEMCITABINE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-27T14:26:00.000+02:00", "crawled": "2018-02-27T14:47:48.030+02:00", "highlightTitle": ""}